Letters Palliative chemotherapy

Optimising end of life care requires an individualised approach

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2312 (Published 25 March 2014) Cite this as: BMJ 2014;348:g2312
  1. Hilde M Buiting, researcher in palliative decision-making1,
  2. Gabe S Sonke, medical oncologist2
  1. 1Comprehensive Cancer Centre the Netherlands (IKNL), Rochussentraat 125, 3015 EJ Rotterdam, Netherlands
  2. 2Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
  1. h.buiting{at}iknl.nl

Wright and colleagues conclude that patients receiving palliative chemotherapy who have an estimated life expectancy of six months are more likely than those not receiving palliative chemotherapy to experience intensive medical end of life care.1 The authors previously showed that end of life discussions in early stage disease are associated with decreased “aggressive” care.2 We support the identification of early predictors for intensive medical …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe